Oppenheimer Keeps Their Buy Rating on Immuneering (IMRX)

Oppenheimer analyst Jay Olson maintained a Buy rating on Immuneering (IMRX – Research Report) today and set a price target of $25.00. The company’s shares closed last Friday at $1.45.

According to TipRanks, Olson is a 5-star analyst with an average return of 17.5% and a 43.33% success rate. Olson covers the Healthcare sector, focusing on stocks such as Ionis Pharmaceuticals, ACADIA Pharmaceuticals, and Biogen.

Currently, the analyst consensus on Immuneering is a Moderate Buy with an average price target of $11.83, a 715.86% upside from current levels. In a report released on May 8, Needham also maintained a Buy rating on the stock with a $15.00 price target.

The company has a one-year high of $11.92 and a one-year low of $1.38. Currently, Immuneering has an average volume of 788.4K.

Based on the recent corporate insider activity of 15 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of IMRX in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Immuneering (IMRX) Company Description:

Immuneering Corpbiopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company’s proprietary computational Disease Cancelling Technology platform enables Immuneering’s drug discovery programs. The company also provides unparalleled computational biology capabilities to leading pharmaceutical and biotechnology companies.